AbstractHIVViral Hepatitis and Liver DiseaseReview on drug interactions of ART and tuberculosis medicationsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSteady-State Plasma Tfv/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily Tdf/FtcView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePlasma and Breastmilk Pharmacokinectics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in UgandaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTime Course of Tenofovir-Diphosphate Carryover in DBS Following TDF to TAF SwitchView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePopulation Pharmacokinetics of HIV-specific Broadly Monoclonal Neutralizing Long-acting Antibody, VRC01LS, in Term InfantsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIn-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment with PBPK ModelsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEffect of Multiple-Dose Itraconazole on the Pharmacokinetics of Single-Dose JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy VolunteersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLedipasvir PK-PD (Pharmacokinetics - Pharmacodynamics): Relationship Between Drug Exposure and Sustained Virologic Response Rates in a Cohort of Patients With Decompensated Cirrhosis and HCV Genotype 1 InfectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseExploring the Role of Age in Transporter-Related Drug-Drug InteractionsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseGenetic Associations With Weight Gain Among South Africans Who Initiated Dolutegravir- and Tenofovir-Containing Regimens in the ADVANCE StudyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseRifabutin Pharmacokinetics and Safety Among TB/HIV Coinfected Young Children Receiving LopinavirView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePopulation Pharmacokinetic Modelling of Atazanavir in Plasma and Hair of HIV-Infected WomenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImpact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers: A Preliminary AnalysisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseDoes Dolutegravir Causes Weight Gain?: A Retrospective Observational Cohort Study From Lusaka, ZambiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseThe Pharmacokinetics (PK) of DOVATO (50 mg Dolutegravir (DTG)/ 300 mg Lamivudine (3TC)) Fixed-Dose Combination in HIV-Infected PatientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEvaluation of Relationships Between AB-506 Related ALT Elevations and AB-506 Pharmacokinetics (PK), Metabolite Concentrations and Plasma Bile AcidsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetics, Safety, and Tolerability of Dolutegravir + Rilpivirine (JULUCA) in Healthy Japanese AdultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseDolutegravir (DTG) Plasma Concentrations Under Different Combinations Regimens for ART- Pre-Treated Adults Living With HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTacrolimus and Sirolimus Doses in an HIV-Infected, Kidney-Recipient, Patient Requiring a Cobicistat-Based Antiretroviral RegimenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSystematic Review and Meta-Analysis of Adverse Perinatal Outcomes Associated With Prenatal Exposure to Protease Inhibitor Combination in Pregnant Women With HIV InfectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIn Utero Exposure to Antiretroviral Drugs and Pregnancy Outcomes: A Secondary Analysis of the ANRS Pharmacovigilance Database From the ANRS-Sponsored HIV Research StudiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImpact of the Hepatitis B Virus (HBV) Capsid Inhibitor, AB-506, on the Single Dose Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTargeting Nuclear Receptors to Prevent Cobicistat HepatotoxicityView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseComparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible TabletsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseImpact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of AgeView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseMechanistic Modelling for the Quantitative Evaluation of ARV Penetration in Lymphatic TissuesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTFVdp/FTCtp Concentrations in Rectal Samples: No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ CellsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIntracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study DesignView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInflammation Affects Antiretrovirals Plasma and Intracellular ExposureView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel (LNG)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and DolutegravirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAntiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and RilpivirineView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseFostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 InfectionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseOpen-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy ParticipantsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of Jnj-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy VolunteersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSingle-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV)View Abstract
